Biosimilar and interchangeable: Inseparable scientific concepts?-Reference-Cited by-同舟云学术

Biosimilar and interchangeable: Inseparable scientific concepts?

Published:2019-09-04 Issue:11 Volume:85 Page:2460-2463
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Mora Fernando¹^ORCID,Balsa Alejandro²^ORCID,Cornide‐Santos María³,Carrascosa Jose‐Manuel⁴^ORCID,Marsal Sara⁵,P. Gisbert Javier⁶^ORCID,Abad Miguel‐Angel⁷,F. Duarte Rafael⁸,Wiechmann Michael⁹,Martínez Rafael¹⁰

Affiliation:

1. Department of Pharmacology, Therapeutics and ToxicologyUniversidad Autónoma de Barcelona Barcelona Spain

2. Hospital La paz, Rheumatology Unit, Instituto de Investigación Sanitaria IdiPAZ, Madrid Spain

3. Medical OncologyHospital General de Segovia Segovia Spain

4. DermatologyHospital Universitari Germans Trias i Pujol Barcelona Spain

5. Rheumatology DepartmentHospital Universitari Vall d'Hebron Barcelona Spain

6. Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS‐IP)Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) Madrid Spain

7. FEA ReumatologíaHospital Virgen del Puerto Plasencia Spain

8. Hematology DepartmentHospital Universitario Puerta de Hierro Majadahonda Majadahonda Spain

9. Global Medical Affairs, Sandoz Biopharmaceutical, Holzkirchen, Germany

10. Medical Affairs Department, Sandoz Iberia, Madrid, Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14089

Reference29 articles.

1. European Medicines Agency and the European Commission. Biosimilars in the EU Information guide for healthcare professionals.2017. Available from:https://www.ema.europa.eu/documents/leaflet/biosimilars‐eu‐information‐guide‐healthcare‐professionals_es.pdf. Accessed February 19 2019.

2. The structure-function relationship of disulfide bonds in etanercept

3. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar

4. Maintaining consistent quality and clinical performance of biopharmaceuticals

5. Differences in sialic acid O-acetylation between human urinary and recombinant erythropoietins: a possible mass spectrometric marker for doping control

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. INVESTIGATING THE PHYSICOCHEMICAL, NON-CLINICAL, AND CLINICAL CRITERIA FOR ASSESSING COMPARABILITY IN RANIBIZUMAB BIOSIMILARS: A COMPREHENSIVE REVIEW;FARMACIA;2024

2. Overview of Biosimilars;Biosimilars for Cancer Treatment;2024

3. Carrier-Mediated Delivery of Low-Molecular-Weight N-Containing Drugs across the Blood–Brain Barrier or the Blood–Retinal Barrier Using the Proton-Coupled Organic Cation Antiporter;Future Pharmacology;2023-10-12

4. A PHARMACEUTICAL GUIDE TO ADALIMUMAB BIOSIMILARS;FARMACIA;2022-06-26

5. [Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy;Actas Dermo-Sifiliográficas;2022-03